Background: A plethora of data supports HPV-based screening to be the preferred strategy for cervical cancer prevention. The shift to a more sensitive firstline test brings the need of effective triage up for discussion. Currently, most algorithms apply cytology as triage of HPV-DNA positive women. This study compared the performance of a 7-type HPV-mRNA test to cytology. Methods: From 2019-01-01, until 2021-12-31, cervical samples from 58,029 women were examined at the University Hospital of North Norway. 30.5% (17,684/58,029) fulfilled the criteria for HPV-DNA primary screening. All positive samples were triaged by cytology and followed-up according to national guidelines. Additionally, a 7-type HPV-mRNA test was applied. Study endpoint was histologically confirmed high grade lesion (CIN2+). Results: 5.6% (990/17,684) had positive HPV-DNA test, 97.2% (962/990) with valid HPV-mRNA results. 55.5% (534/962) had abnormal cytology (ASC-US+) and 35.1% (338/962) had positive HPV-mRNA test. 9.8% (94/962) had CIN2+. Sensitivity (CIN2+) of cytology versus the HPV-mRNA test was 83.0% (78/94) versus 76.6% (72/94), p=0.36. The specificity was 47.5% (412/868) versus 69.4% (602/868), p<0.001. PPV was 14.6% (78/534) and 21.3% (72/338), p=0.014 respectively. The number of colposcopies per CIN2+ detected by cytology and HPV-mRNA test was 6.8 and 4.7. Conclusion: The 7-type HPV mRNA test was more specific than cervical cytology in triage of HPV-DNA positive women. Using this biomarker as threshold for colposcopy may better balance the benefits and harms of screening.